{"id":453,"date":"2018-12-03T12:38:23","date_gmt":"2018-12-03T11:38:23","guid":{"rendered":"https:\/\/www.degro.org\/ag-stereotaxie\/?page_id=453"},"modified":"2023-07-19T17:41:49","modified_gmt":"2023-07-19T15:41:49","slug":"sbrt-for-adrenal-metastases","status":"publish","type":"page","link":"https:\/\/www.degro.org\/ag-stereotaxie\/projekte\/aktuelle-projekte\/sbrt-for-adrenal-metastases\/","title":{"rendered":"SBRT for adrenal metastases"},"content":{"rendered":"<div id=\"pl-453\"><style scoped>#pg-453-0 .panel-grid-cell { float:none } #pl-453 .panel-grid-cell .so-panel { margin-bottom:30px } #pl-453 .panel-grid-cell .so-panel:last-child { margin-bottom:0px } #pg-453-0 { margin-left:-15px;margin-right:-15px } #pg-453-0 .panel-grid-cell { padding-left:15px;padding-right:15px } #panel-453-0-0-0 a { color:#009cd8 } @media (max-width:780px){ #pg-453-0 .panel-grid-cell { float:none;width:auto } #pl-453 .panel-grid , #pl-453 .panel-grid-cell {  } #pl-453 .panel-grid .panel-grid-cell-empty { display:none } #pl-453 .panel-grid .panel-grid-cell-mobile-last { margin-bottom:0px }  } <\/style><div class=\"panel-grid\" id=\"pg-453-0\" ><div class=\"panel-grid-cell\" id=\"pgc-453-0-0\" ><div class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" id=\"panel-453-0-0-0\" data-index=\"0\"><div class=\"so-widget-sow-editor so-widget-sow-editor-base\">\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<h2>Stereotactic body radiotherapy (SBRT) <strong>of adrenal metastases <\/strong><\/h2>\n<hr \/>\n<h4 class=\"accordion-item open\"><span id=\"DeltaPlaceHolderMain\"><strong>Sponsor-Investigator:<\/strong><br \/>\n<\/span><span id=\"DeltaPlaceHolderMain\"><\/span><\/h4>\n<p class=\"accordion-item open\"><span id=\"DeltaPlaceHolderMain\">PD Dr. Judit Boda-Heggemann \/PD Dr. Daniel Buergy<br \/>\n<\/span>Universit\u00e4tsmedizin Mannheim<br \/>\n<span id=\"DeltaPlaceHolderMain\"><a href=\"mailto:daniel.buergy@medma.uni-heidelberg.de\">daniel.buergy@medma.uni-heidelberg.de<\/a><br \/>\n<\/span><span id=\"DeltaPlaceHolderMain\"><\/span><\/p>\n<h4><span id=\"DeltaPlaceHolderMain\"><strong>Study objective:<\/strong><\/span><\/h4>\n<p><span id=\"DeltaPlaceHolderMain\">To analyze the toxicity and efficacy of targeted radiotherapy to adrenal metastases<\/span><\/p>\n<p><strong>Project status<\/strong><\/p>\n<ul>\n<li>Data collection completed<\/li>\n<li>Two full articles published<\/li>\n<\/ul>\n<p><strong>Major findings and results<\/strong><\/p>\n<p>Buergy D, W\u00fcrschmidt F, Gkika E, et al. <strong>Stereotactic body radiotherapy of adrenal metastases-A dose-finding study.<\/strong> Int J Cancer. 2022; 151(3):412-421.\u00a0 <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35383919\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/35383919\/<\/a><\/p>\n<ul>\n<li>Dose-volume parameters available in 218 patients treated with SBRT<\/li>\n<li>Biologically effective dose (BED10) cut-point analyses indicated optimal dose cut-points as follows:\n<ul>\n<li>PTV-D50%: 73.2 Gy<\/li>\n<li>PTV-D2%: 78.0 Gy<\/li>\n<li>GTV-D50%: 74.2 Gy<\/li>\n<li>GTV-mean: 73.0 Gy<\/li>\n<\/ul>\n<\/li>\n<li>If these dose levels were achieved, local recurrence rates (LRR) were significantly reduced compared to patients who received lower doses.<\/li>\n<li>Further dose escalation was not associated with improved LRR in our patient cohort (e.g., PTV-D50% values of 73.2-85.9 Gy compared to doses above 85.9 Gy)<\/li>\n<\/ul>\n<p>Buergy D, W\u00fcrschmidt F, Gkika E, et al. <strong>Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis<\/strong><strong>. <\/strong>Int J Cancer. 2021; 149(2):358-370. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33682927\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/33682927\/<\/a><\/p>\n<ul>\n<li><strong>\u00a0<\/strong>366 lesions included in the analysis (260 treated with SBRT)<\/li>\n<li>Toxicity mostly mild; however, four cases of adrenal insufficiency occurred, 2 of which were likely caused by immunotherapy or tumor progression<\/li>\n<li>Freedom from local progression after one year was associated with improved overall survival<\/li>\n<\/ul>\n<h4><strong>Project status:<\/strong><\/h4>\n<ul>\n<li>Study closed (219 patients recruited)<\/li>\n<li>Follow-up ongoing<\/li>\n<\/ul>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>#pg-453-0 .panel-grid-cell { float:none } #pl-453 .panel-grid-cell .so-panel { margin-bottom:30px } #pl-453 .panel-grid-cell .so-panel:last-child { margin-bottom:0px } #pg-453-0 { margin-left:-15px;margin-right:-15px } #pg-453-0 .panel-grid-cell { padding-left:15px;padding-right:15px } #panel-453-0-0-0 a { color:#009cd8 } @media (max-width:780px){ #pg-453-0 .panel-grid-cell { float:none;width:auto } #pl-453 .panel-grid <\/p>\n","protected":false},"author":8,"featured_media":0,"parent":77,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/pages\/453"}],"collection":[{"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/comments?post=453"}],"version-history":[{"count":18,"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/pages\/453\/revisions"}],"predecessor-version":[{"id":966,"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/pages\/453\/revisions\/966"}],"up":[{"embeddable":true,"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/pages\/77"}],"wp:attachment":[{"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/media?parent=453"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}